- Home
- COF vs GILD Comparison
COF vs GILD Comparison
Compare COF & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COF | GILD |
|---|---|---|
| Founded | 1988 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.8B | 147.6B |
| IPO Year | 1994 | 1992 |
Fundamental Metrics
Financial Performance| Metric | COF | GILD |
|---|---|---|
| Price | $240.13 | $119.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 20 |
| Target Price | ★ $252.12 | $127.10 |
| AVG Volume (30 Days) | 4.1M | ★ 7.0M |
| Earning Date | 01-20-2026 | 10-30-2025 |
| Dividend Yield | 1.34% | ★ 2.62% |
| EPS Growth | N/A | ★ 6514.05 |
| EPS | 2.38 | ★ 6.42 |
| Revenue | $28,886,000,000.00 | ★ $29,087,000,000.00 |
| Revenue This Year | $96.76 | $3.63 |
| Revenue Next Year | $18.32 | $2.97 |
| P/E Ratio | $99.92 | ★ $18.75 |
| Revenue Growth | ★ 9.02 | 2.79 |
| 52 Week Low | $143.22 | $88.57 |
| 52 Week High | $243.31 | $128.70 |
Technical Indicators
Market Signals| Indicator | COF | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 72.33 | 43.72 |
| Support Level | $236.01 | $119.53 |
| Resistance Level | $243.31 | $123.74 |
| Average True Range (ATR) | 5.29 | 2.58 |
| MACD | 2.21 | -0.71 |
| Stochastic Oscillator | 90.37 | 12.31 |
Price Performance
Historical ComparisonAbout COF Capital One Financial Corporation
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending. Following the acquisition of Discover in 2025, the firm also has a modest personal loan business, though credit card lending still provides the majority of the bank's revenue.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).